ADARx Pharmaceuticals (ADRX) vs Damora Therapeutics (DMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.42 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | DMRA |
|---|---|---|
| Share price | $12.79 | $23.22 |
| Market cap | $1.42B | $1.44B |
| 1-day change | -9.68% | -4.44% |
| YTD return | — | +0.91% |
| 1-year return | — | +38.46% |
| 5-year return | — | -68.83% |
| P/E ratio (TTM) | — | 13.58 |
| EPS (TTM) | $-6.75 | $1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-209.84M |
| 52-week high | $23.21 | $38.33 |
| 52-week low | $12.50 | $15.76 |
| Distance from 52-week high | -44.89% | -39.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +167.79% | +101.46% |
| Average volume | 650.63K | 584.28K |
| Shares outstanding | 111.19M | 61.90M |
| Employees | 100 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ADRX vs DMRA FAQ
Which is bigger, ADARx Pharmaceuticals or Damora Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.42B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Damora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.